vtama news - Search News

GlobalData on MSN · 22h

Organon makes $1.2bn play for Roivant’s immuno-dermatology subsidiary

As part of the acquisition, Organon will acquire psoriasis treatment Vtama, which could soon be approved in atopic dermatitis.

Seeking Alpha · 18h

Roivant's Sale Of Dermavant To Organon: A Strategic Win-Win In Atopic Dermatitis

Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click here to read my most recent analysis.

Organon to acquire Dermavant in $1.2B deal

The Roivant company is dedicated to developing and commercializing innovative therapeutics in immune-dermatology.

MarketWatch · 2d

Organon to Buy Roivant's Dermavant Unit in Deal Worth Up to $1.2 Billion

Organon has agreed to buy medical dermatology company Dermavant Sciences, a majority-owned unit of Roivant Sciences, in a deal worth up to $1.2 billion. Organon on Wednesday said it will make an up-front payment of $175 million, along with up to $1.025 billion in milestone payments.

MT Newswires on MSN · 2d

Organon to Buy Roivant's Dermatology Unit For Up to $1.2 Billion

Organon (OGN) on Wednesday agreed to acquire Roivant Sciences' (ROIV) immuno-dermatology subsidiary, Dermavant, in a deal worth up to $1.2 billion. The healthcare company will pay $175 million upfront and up to $950 million for the achievement of certain commercial milestones.

1don MSN

Roivant Flips a Skin Drug to Organon

Selling plaque psoriasis drug Vtama to Organon looks like another win for Roivant, which has been buying overlooked drugs, ...

Organon to buy Dermavant Sciences including its innovative dermatologic therapy, Vtama cream 1% to treat plaque psoriasis

Basel, Switzerland Friday, September 20, 2024, 13:00 Hrs [IST] ...

1d

Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B

Organon is set to acquire Roivant Sciences' Dermavant Sciences, known for developing immuno-dermatology treatments, including ...

Organon pays up to $1.2B to acquire Dermavant and its steroid-free skin cream Vtama

Organon will also furnish Dermavant with a $75 million milestone payment contingent upon Vtama’s approval in atopic ...

2d

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an ...

Organon makes dermatology play with $1.2bn Dermavant buyout

Organon is paying $175 million upfront to buy Roivant's dermatology unit Dermavant and its topical psoriasis therapy Vtama, ...

Skin deep: Organon buys Dermavant for $1.2B

Roivant Sciences Ltd. has sold another company, this time offering up Dermavant Sciences Ltd. to Organon & Co. for $1.2 ...

1d

Strong Buy Rating for Roivant Sciences Backed by Strategic Dermavant Divestiture and Promising Clinical Pipeline

Goldman Sachs analyst Chris Shibutani has maintained their bullish stance on ROIV stock, giving a Buy rating today. Chris Shibutani has given ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results